The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2020 | Managing comorbidities in lung cancer patients
Dirk De Ruysscher, MD, PhD, Maastricht University Medical Center, Maastricht, Netherlands outlines the challenges of managing comorbidities and toxicities in lung cancer patients at the ESMO 2020 education weekend. Dr Ruysscher specifically discusses how radiotherapy and chemotherapy contribute to the development of esophagitis, the metabolic impacts esophagitis has in lung cancer patients and how nutrition and exercise management strategies can be integrated into routine clinical care to improve prognosis. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).
